Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation

D B Drachman, C W Angus, R N Adams, J D Michelson, G J Hoffman

Research output: Contribution to journalArticlepeer-review

297 Citations (Scopus)


The decrease of acetylcholine receptors at neuromuscular junctions of myasthenic patients has been attributed to an antibody-mediated autoimmune process that accelerates receptor degradation. We studied the mechanism of this process in skeletal-muscle cultures, using intact antibodies and antibody fragments. Addition of myasthenic IgG or its divalent fragment, F(ab')2, to cultures accelerated the rate of acetylcholine-receptor degradation threefold. By contrast, the monovalent fragment, Fab, from myasthenic serum had no effect on degradation, although it bound to acetylcholine receptors. Addition of a second, "piggyback" antibody to cross-link the Fab:receptor complexes resulted in a threefold increase of the degradation rate. Similarly, when acetylcholine receptors with bound alpha-bungarotoxin were cross-linked by the addition of specific antibody against alpha-bungarotoxin, the degradation rate increased approximately threefold. The effect of myasthenic patients' antibodies in accelerating degradation of acetylcholine receptors is attributed to their ability to cross-link the receptors.

Original languageEnglish
Pages (from-to)1116-22
Number of pages7
JournalThe New England Journal of Medicine
Issue number20
Publication statusPublished - 18 May 1978


Dive into the research topics of 'Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation'. Together they form a unique fingerprint.

Cite this